CXCL9 and localized scleroderma: The significant correlation of ANA and associated extrable nuclear autoantibodies with the depth of tissue involvement, extracutanous manifestations and potential for relapse in morphea, places ANA as a potential biomarker for morphea disease stratification and management, either individually or as a composite indictor with clinical variables, such as the mLoSSI, and other immune markers, such as cytokines of interest in the field, CXCL9 and CXCL10 (30, 31).